- $3.33bn
- $2.94bn
- $618.73m
- 61
- 19
- 53
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.49 | ||
| Price to Tang. Book | 4.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.38 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.66% | ||
| Return on Equity | -32.98% | ||
| Operating Margin | -42.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 245.89 | 298.85 | 490.49 | 516.41 | 618.73 | 677.79 | 791.18 | 33.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Directors
- John Stuelpnagel NEC (63)
- Benjamin Hindson PRE (46)
- Serge Saxonov CEO (44)
- Justin McAnear CFO (45)
- Jean Philibert CHO (61)
- Eric Whitaker GCN (54)
- Bradford Crutchfield OTH (58)
- Ruth De Backer OTH (44)
- Sridhar Kosaraju IND (43)
- Mathai Mammen IND (53)
- Kimberly Popovits IND (62)
- Bryan Roberts IND (54)
- Shehnaaz Suliman IND (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 2nd, 2012
- Public Since
- September 12th, 2019
- No. of Shareholders
- 57
- No. of Employees
- 1,259
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 119,166,544
- Address
- 6230 Stoneridge Mall Road, PLEASANTON, 94588
- Web
- https://www.10xgenomics.com/
- Phone
- +1 9254017300
- Auditors
- Ernst & Young LLP
Upcoming Events for TXG
Q1 2024 10X Genomics Inc Earnings Call
10X Genomics Inc Annual Shareholders Meeting
10X Genomics Inc Annual Shareholders Meeting
Q2 2024 10X Genomics Inc Earnings Release
Similar to TXG
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
Angiodynamics
NASDAQ Global Select Market
FAQ
What is the 10X Genomics share price?
As of Today at 19:00 UTC, shares in 10X Genomics are trading at $27.94. This share price information is delayed by 15 minutes.
How has the 10X Genomics share price performed this year?
Shares in 10X Genomics last closed at $27.94 and the price had moved by -47.45% over the past 365 days. In terms of relative price strength the 10X Genomics share price has underperformed the S&P500 Index by -56.27% over the past year.
What are the analyst and broker recommendations for 10X Genomics?
The overall consensus recommendation for 10X Genomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the 10X Genomics dividend yield?
10X Genomics does not currently pay a dividend.
Does 10X Genomics pay a dividend?
10X Genomics does not currently pay a dividend.
When does 10X Genomics next pay dividends?
10X Genomics does not currently pay a dividend.
How do I buy 10X Genomics shares?
To buy shares in 10X Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 10X Genomics?
As of the previous close price of $27.94, shares in 10X Genomics had a market capitalisation of $3.33bn.
Where are 10X Genomics shares listed?
Here are the trading details for 10X Genomics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TXG
What kind of share is 10X Genomics?
Based on an overall assessment of its quality, value and momentum 10X Genomics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 10X Genomics share price forecast for 2024?
The analyst consensus target price for shares in 10X Genomics is $53.57. That is 91.73% above the last closing price of $27.94.
Analysts covering 10X Genomics currently have a consensus Earnings Per Share (EPS) forecast of -$1.60 for the next financial year.
What is the trend in the 10X Genomics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 10X Genomics. Over the past six months, its share price has underperformed the S&P500 Index by -39.86%.
As of the last closing price of $27.94, shares in 10X Genomics were trading -38.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 10X Genomics PE Ratio?
The 10X Genomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $27.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 10X Genomics?
10X Genomics' management team is headed by:
- John Stuelpnagel - NEC
- Benjamin Hindson - PRE
- Serge Saxonov - CEO
- Justin McAnear - CFO
- Jean Philibert - CHO
- Eric Whitaker - GCN
- Bradford Crutchfield - OTH
- Ruth De Backer - OTH
- Sridhar Kosaraju - IND
- Mathai Mammen - IND
- Kimberly Popovits - IND
- Bryan Roberts - IND
- Shehnaaz Suliman - IND